OR WAIT null SECS
The two companies signed an exclusive collaboration agreement for the Aidaptus auto-injector.
Owen Mumford, a medical device manufacturer, announced on May 4, 2022 that it has signed an exclusive agreement with Stevanato Group, a provider of drug containment, drug delivery, and diagnostic solutions, to manufacture the Aidaptus auto-injector. Aidaptus is a two-step, single-use auto-injector that can accommodate 1 mL and 2.25 mL prefilled glass syringes in the same base device.
Based on the agreement, components for the Aidaptus will be molded by Stevanato Group, which will also provide final and sub-assembly equipment. Stevanato Group will also offer pre-filled syringes to create final product for patient use. Owen Mumford and Stevanato will both assemble components for the auto-injector. According to the company, the collaboration will bring added value to customers and streamline device production.
“Aidaptus will help patients to self-administer their individual therapies using a simple and easy to use device,” said Adam Mumford, director of Owen Mumford, in a press release. “At the same time, this auto-injector can help to reduce complexity, minimize supply chain risk, and simplify final assembly for pharmaceutical and biotechnology companies thanks to its ability to adapt to different viscosity, syringe sizes, and fill volumes. Often during development or life-cycle management of injectable drug products, changes in these parameters can occur. Now for the first time, the device does not have to be changed as well.”
"We believe this agreement is an important step in enhancing and growing the opportunities in our drug delivery systems portfolio as we broaden our capabilities in this key market. As we are constantly working with our customers to satisfy their needs, we continue to experience an increase in demand for auto-injectors. With this agreement, we will exploit the full breadth of Stevanato Group integrated capabilities being able to offer device manufacturing, assembly equipment, together with pre-fillable syringes and inspection systems," said Mauro Stocchi, chief business officer of Stevanato Group, in the release.
“Stevanato Group is an established company with an excellent reputation in the pharmaceutical industry,” said Michael Earl, director of Pharmaceutical Services at Owen Mumford. “It has deep expertise in molding and assembly operations and will be a reliable source of quality components for our Aidaptus auto-injector. Forming a collaboration with Stevanato Group will provide additional reach to enable more customers to benefit from the advantages of this innovative new platform.”
"The Aidaptus auto-injector platform combines ease of use for patients with faster time-to-market access for pharma organizations. We aim to be the strategic partner with which to develop innovative combination products as we continue the expansion of our integrated capabilities in the drug delivery space, and for this reason we are very excited to work with Owen Mumford and provide access to its exciting new auto-injector platform,” said Steven Kaufman, VP for Drug Delivery Systems at Stevanato Group.
Source: Owen Mumford